Provided by Tiger Fintech (Singapore) Pte. Ltd.

uniQure NV

14.55
+0.15001.04%
Pre-market: 14.700.1500+1.03%04:29 EDT
Volume:1.14M
Turnover:16.67M
Market Cap:796.59M
PE:-3.33
High:14.87
Open:14.48
Low:14.31
Close:14.40
Loading ...

uniQure Price Target Maintained With a $70.00/Share by HC Wainwright & Co.

Dow Jones
·
05 Mar

uniQure Full Year 2024 Earnings: Misses Expectations

Simply Wall St.
·
01 Mar

uniQure Is Maintained at Equal-Weight by Wells Fargo

Dow Jones
·
01 Mar

Uniqure NV reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
27 Feb

uniQure (QURE) Receives a Buy from William Blair

TIPRANKS
·
27 Feb

UniQure (QURE) Reports Q4 Loss, Misses Revenue Estimates

Zacks
·
27 Feb

uniQure FY 2024 GAAP EPS $(4.92) Misses $(3.99) Estimate, Sales $27.12M Miss $39.44M Estimate

Benzinga
·
27 Feb

uniQure Announces 2024 Financial Results and Highlights Recent Company Progress

GlobeNewswire
·
27 Feb

uniQure N.V. (NASDAQ:QURE) is a favorite amongst institutional investors who own 66%

Simply Wall St.
·
20 Feb

uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years

Benzinga
·
08 Feb

UniQure Advances AMT-191 Trial in Fabry Disease

MT Newswires Live
·
04 Feb

uniQure completes enrollment in first cohort of Phase I/IIa trial of AMT-191

TIPRANKS
·
03 Feb

uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease

GlobeNewswire
·
03 Feb

UniQure Gets Favorable Recommendation From Data Monitoring Committee AMT-162 Trial to Treat Amyotrophic Lateral Sclerosis

MT Newswires Live
·
30 Jan

uniQure says IDMC recommends proceeding with dose escalation in AMT-162 trial

TIPRANKS
·
30 Jan

uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS

GlobeNewswire
·
30 Jan

Is uniQure N.V. (QURE) the Most Promising Growth Stock According to Wall Street Analysts?

Insider Monkey
·
28 Jan

uniQure Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
27 Jan

uniQure Price Target Maintained With a $24.00/Share by RBC Capital

Dow Jones
·
22 Jan

uniQure (QURE) Gets a Buy from Wells Fargo

TIPRANKS
·
16 Jan